ProMIS Neurosciences Inc.

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PMN and other ETFs, options, and stocks.

About PMN

ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. 

CEO
Neil K. Warma
CEONeil K. Warma
Employees
7
Employees7
Headquarters
Toronto, Ontario
HeadquartersToronto, Ontario
Founded
2004
Founded2004
Employees
7
Employees7

PMN Key Statistics

Market cap
30.99M
Market cap30.99M
Price-Earnings ratio
-0.76
Price-Earnings ratio-0.76
Dividend yield
Dividend yield
Average volume
818.37K
Average volume818.37K
High today
$21.94
High today$21.94
Low today
$12.49
Low today$12.49
Open price
$18.69
Open price$18.69
Volume
7.93M
Volume7.93M
52 Week high
$39.75
52 Week high$39.75
52 Week low
$6.27
52 Week low$6.27

Stock Snapshot

With a market cap of 30.99M, ProMIS Neurosciences Inc.(PMN) trades at $12.49. The stock has a price-to-earnings ratio of -0.76.

On 2026-02-02, ProMIS Neurosciences Inc.(PMN) stock moved within a range of $12.49 to $21.94. With shares now at $12.49, the stock is trading 0.0% above its intraday low and -43.1% below the session's peak.

Trading activity shows a volume of 7.93M, compared to an average daily volume of 818.37K.

The stock's 52-week range extends from a low of $6.27 to a high of $39.75.

The stock's 52-week range extends from a low of $6.27 to a high of $39.75.

PMN News

Nasdaq 3d
ProMIS Neurosciences Secures $175 Mln In Private Financing

(RTTNews) - ProMIS Neurosciences Inc. (PMN), a clinical-stage biotechnology company, has announced on Friday a private investment in public equity financing of...

ProMIS Neurosciences Secures $175 Mln In Private Financing
TipRanks 3d
ProMIS Neurosciences Announces $75 Million PIPE Financing

ProMIS Neurosciences ( (PMN) ) has provided an update. On January 30, 2026, ProMIS Neurosciences announced it had entered into a private investment in public e...

People also own

Based on the portfolios of people who own PMN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.